{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:08:50Z","timestamp":1788876530588,"version":"build-2803163510"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000261","name":"MS Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jneuroim.2026.579043","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:19:08Z","timestamp":1785453548000},"page":"579043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Epstein\u2013Barr virus and multiple sclerosis: Mechanisms, therapeutic implications, and emerging interventions"],"prefix":"10.1016","volume":"420","author":[{"given":"Mohamed Reda","family":"Fazazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Champagne-Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamanna","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tweed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2026.579043_bb0005","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/jnnp-2020-322941","article-title":"Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis","volume":"91","author":"Abrahamyan","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0010","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/ene.13622","article-title":"Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the \u2018hygiene hypothesis\u2019?","volume":"25","author":"Alari-Pahissa","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0015","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu5110","article-title":"Epstein-Barr virus infection promotes T cell dysregulation in a humanized mouse model of multiple sclerosis","volume":"11","author":"Allanach","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113048","article-title":"HHV-6 and EBV reactivation in relapsing remitting multiple sclerosis: disability, progression, and inflammation links","volume":"28","author":"Almulla","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(22)00471-9","article-title":"Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy","volume":"22","author":"Aloisi","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s11481-013-9448-6","article-title":"The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of \u03b3-herpesvirus infected B cells in the marmoset EAE model","volume":"8","author":"Anwar Jagessar","year":"2013","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0035","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","article-title":"Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study","volume":"286","author":"Ascherio","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0040","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ana.22449","article-title":"Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate","volume":"70","author":"Axthelm","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.neurol.2021.11.009","article-title":"Genetics and familial distribution of multiple sclerosis: a review","volume":"178","author":"Balcerac","year":"2022","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0050","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","article-title":"Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0055","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0060","doi-asserted-by":"crossref","first-page":"27101","DOI":"10.1074\/jbc.M115.649582","article-title":"Antigen-B cell receptor complexes associate with intracellular major histocompatibility complex (MHC) class II molecules","volume":"290","author":"Barroso","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.58.1.31","article-title":"A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS","volume":"58","author":"Bech","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/1352458519872664","article-title":"Environmental factors and risk of multiple sclerosis: findings from meta-analyses and Mendelian randomization studies","volume":"26","author":"Belbasis","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.869447","article-title":"Natural killer cells in multiple sclerosis: entering the stage","volume":"13","author":"Beli\u00ebn","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0080","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1177\/1352458512454774","article-title":"Evaluating cognitive outcome measures for MS clinical trials: what is a clinically meaningful change?","volume":"18","author":"Benedict","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0085","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.11.026","article-title":"Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis","volume":"291","author":"Blair","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103760","article-title":"Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"61","author":"Bose","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0100","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001012","article-title":"Anti-CD20 depletes meningeal B cells but does not halt the formation of meningeal ectopic lymphoid tissue","volume":"8","author":"Brand","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16526","article-title":"Treating to target in multiple sclerosis: do we know how to measure whether we hit it?","volume":"31","author":"Bsteh","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0110","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1136\/jnnp.2004.048504","article-title":"Epstein-Barr virus and disease activity in multiple sclerosis","volume":"76","author":"Buljevac","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0115","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","article-title":"Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals","volume":"9","author":"Caldwell","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002715","article-title":"Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to Epstein-Barr virus and multiple sclerosis","volume":"8","author":"Casiraghi","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/srep13995","article-title":"Latent virus infection upregulates CD40 expression facilitating enhanced autoimmunity in a model of multiple sclerosis","volume":"5","author":"Casiraghi","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0130","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/901312","article-title":"Epstein-Barr virus specific antibody response in multiple sclerosis patients during 21 months of Natalizumab treatment","volume":"2015","author":"Castellazzi","year":"2015","journal-title":"Dis. Markers"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0135","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0140","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/femsre\/fuz023","article-title":"Epithelial cell infection by Epstein-Barr virus","volume":"43","author":"Chen","year":"2019","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0145","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.celrep.2013.11.041","article-title":"Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection","volume":"5","author":"Chijioke","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0150","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","article-title":"Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis","volume":"354","author":"Coles","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0155","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/1078-0432.CCR-24-2814","article-title":"First-in-human clinical trial of a small-molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr-positive nasopharyngeal Cancer, with pharmacokinetic and Pharmacodynamic studies","volume":"31","author":"Colevas","year":"2025","journal-title":"Clinical cancer research\u202f: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0160","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103264","article-title":"Acting centrally or peripherally: a renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis","volume":"56","author":"Correale","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0170","doi-asserted-by":"crossref","first-page":"e1950","DOI":"10.1212\/WNL.0000000000009371","article-title":"Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT","volume":"94","author":"Cortese","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10238-009-0063-z","article-title":"Stress-related Epstein-Barr virus reactivation","volume":"10","author":"Coskun","year":"2010","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105344","article-title":"A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis","volume":"81","author":"Dahal","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021386","article-title":"T regulatory cells are markers of disease activity in multiple sclerosis patients","volume":"6","author":"Dalla Libera","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0190","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0195","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1038\/s41467-023-39770-1","article-title":"Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice","volume":"14","author":"Dasari","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0200","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1437","article-title":"From bedside to bench: how existing therapies inform the relationship between Epstein-Barr virus and multiple sclerosis","volume":"12","author":"Dyer","year":"2023","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41541-024-00907-y","article-title":"A gH\/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge","volume":"9","author":"Edwards","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0215","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/JVI.02194-12","article-title":"Genomic characterization of Japanese macaque rhadinovirus, a novel herpesvirus isolated from a nonhuman primate with a spontaneous inflammatory demyelinating disease","volume":"87","author":"Estep","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr virus and Cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0225","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.0b013e3181aa29fe","article-title":"Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI","volume":"73","author":"Farrell","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579043_bb0230","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/clinids\/18.Supplement_1.S79","article-title":"Measuring the functional impact of fatigue: initial validation of the fatigue impact scale","volume":"18","author":"Fisk","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0235","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5603\/PJNNS.a2022.0043","article-title":"Anti-EBNA1 IgG titre is not associated with fatigue in multiple sclerosis patients","volume":"56","author":"Fleischer","year":"2022","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0245","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1191\/1352458505ms1185oa","article-title":"A randomized clinical trial of valacyclovir in multiple sclerosis","volume":"11","author":"Friedman","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0250","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.0000000000006810","article-title":"Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge","volume":"92","author":"Gasperini","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0255","article-title":"EBNA-1 and VCA-p18 immunoglobulin markers link Epstein-Barr virus immune response and brain's myelin content to fatigue in a community-dwelling cohort","volume":"42","author":"Gayer","year":"2024","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0260","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","article-title":"Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents","volume":"119","author":"Ghosh","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175279","article-title":"Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis","volume":"12","author":"Gie\u00df","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105364","article-title":"Emboldened or not: the potential fall-out of a failed anti-EBV trial in multiple sclerosis","volume":"81","author":"Giovannoni","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0275","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/13524585241237707","article-title":"Risk of multiple sclerosis in individuals with infectious mononucleosis: a national population-based cohort study using hospital records in England, 2003-2023","volume":"30","author":"Goldacre","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0280","first-page":"51","article-title":"Substantial subpial cortical demyelination in progressive multiple sclerosis: have we underestimated the extent of cortical pathology?","volume":"7","author":"Griffiths","year":"2020","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0285","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000876","article-title":"EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS","volume":"7","author":"Guerrera","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0290","unstructured":"Guidelines, M. (1998)."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0295","article-title":"Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab","volume":"399","author":"Gurski","year":"2025","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012496","article-title":"An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis","volume":"5","author":"Handel","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0305","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41587-024-02321-0","volume":"42","author":"Harrison","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0310","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0315","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1182\/bloodadvances.2023010330","article-title":"Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b\/2 study","volume":"7","author":"Haverkos","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0320","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0325","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11011-012-9292-z","article-title":"Assessment of Epstein-Barr virus in blood from patients with multiple sclerosis","volume":"27","author":"Hon","year":"2012","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0330","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1177\/1352458509347150","article-title":"Validation of the hospital anxiety and depression scale for use with multiple sclerosis patients","volume":"15","author":"Honarmand","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0335","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2008.12.005","article-title":"Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study","volume":"282","author":"Horakova","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053996","article-title":"Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study","volume":"8","author":"Horakova","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0345","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ncl.2016.06.016","article-title":"Epidemiology of multiple sclerosis","volume":"34","author":"Howard","year":"2016","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0350","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0355","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jnr.20522","article-title":"Decreased FOXP3 levels in multiple sclerosis patients","volume":"81","author":"Huan","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0360","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12985-023-02187-9","article-title":"Epstein-Barr virus infection: the micro and macro worlds","volume":"20","author":"Huang","year":"2023","journal-title":"Virol. J."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0365","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftae002","article-title":"Awakening the sleeping giant: Epstein-Barr virus reactivation by biological agents","volume":"82","author":"Indari","year":"2024","journal-title":"Pathog Dis"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0370","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1468-1331.2010.03083.x","article-title":"Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity","volume":"17","author":"Ingram","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102512","article-title":"Clinical outcome measures in multiple sclerosis: a review","volume":"19","author":"Inojosa","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0380","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"International Multiple Sclerosis Genetics, C","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.652811","article-title":"Sustained clinical improvement in a subset of patients with progressive multiple sclerosis treated with Epstein-Barr virus-specific T cell therapy","volume":"12","author":"Ioannides","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0390","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/NEN.0b013e3182622691","article-title":"B-cell depletion abrogates T cell-mediated demyelination in an antibody-nondependent common marmoset experimental autoimmune encephalomyelitis model","volume":"71","author":"Jagessar","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0395","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11481-012-9384-x","article-title":"Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys","volume":"7","author":"Jagessar","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0400","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1352458519828667","article-title":"Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: a case-controlled magnetization transfer ratio study","volume":"26","author":"Jakimovski","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0405","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.701611","article-title":"Main targets of interest for the development of a prophylactic or therapeutic Epstein-Barr virus vaccine","volume":"12","author":"Jean-Pierre","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0415","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1093\/brain\/awv258","article-title":"Defining reliable disability outcomes in multiple sclerosis","volume":"138","author":"Kalincik","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0420","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0425","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u2018no evidence of disease activity\u2019 (NEDA-4) in relapsing-remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0430","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0435","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jneuroim.2015.11.017","article-title":"25-hydroxyvitamin D levels are associated with multiple sclerosis in Iran: a cross-sectional study","volume":"290","author":"Karampoor","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0440","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdv596","article-title":"Epstein-Barr virus reactivation in extranodal natural killer\/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin","volume":"27","author":"Kim","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0445","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/acn3.293","article-title":"Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis","volume":"3","author":"Komori","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0450","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1191\/1352458505ms1117oa","article-title":"Evaluation of the modified fatigue impact scale in four different European countries","volume":"11","author":"Kos","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0455","first-page":"1308","article-title":"Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis","volume":"20","author":"Kouchaki","year":"2021","journal-title":"EXCLI J."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0460","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/1352458514568827","article-title":"Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study","volume":"21","author":"Kuhle","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0465","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0470","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0475","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/1352458514533843","article-title":"Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis","volume":"20","author":"Kvistad","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0480","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09378-0","article-title":"EBV induces CNS homing of B cells attracting inflammatory T cells","author":"Laderach","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0485","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0490","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0495","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa2516491","article-title":"Efficacy and safety of an mRNA seasonal influenza vaccine in adults","volume":"394","author":"Leroux-Roels","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0500","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0505","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.msard.2017.12.016","article-title":"The evolution of \u201cno evidence of disease activity\u201d in multiple sclerosis","volume":"20","author":"Lu","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0510","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0515","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1084\/jem.20072397","article-title":"EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2","volume":"205","author":"Lunemann","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0520","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ana.21886","article-title":"Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis","volume":"67","author":"L\u00fcnemann","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0525","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF00868517","article-title":"Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study","volume":"243","author":"Lycke","year":"1996","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0530","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0535","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0540","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/NEN.0b013e31827bfc62","article-title":"B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis","volume":"72","author":"Magliozzi","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0545","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41582-023-00838-7","article-title":"Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis","volume":"19","author":"Magliozzi","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0550","article-title":"Immunization with a self-assembling nanoparticle vaccine displaying EBV gH\/gL protects humanized mice against lethal viral challenge","volume":"3","author":"Malhi","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0555","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/1352458515601215","article-title":"Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis","volume":"22","author":"Mart\u00ednez-Rodr\u00edguez","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0560","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2014.02.001","article-title":"Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations","volume":"151","author":"Miyazaki","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0565","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000466","article-title":"Molecular signature of Epstein-Barr virus infection in MS brain lesions","volume":"5","author":"Moreno","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0570","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0575","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0404.1998.tb00632.x","article-title":"The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients?","volume":"97","author":"Munch","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0580","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1212\/WNL.0000000000002099","article-title":"No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT","volume":"85","author":"Munger","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0585","article-title":"Immune control of human \u03b3-herpes infections","volume":"64s","author":"M\u00fcnz","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0590","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00430-015-0437-7","article-title":"EBV and vitamin D status in relapsing-remitting multiple sclerosis patients with a unique cytokine signature","volume":"205","author":"Nejati","year":"2016","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0595","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/aian.AIAN_159_19","article-title":"No evidence of disease activity (NEDA) in multiple sclerosis - shifting the goal posts","volume":"22","author":"Pandit","year":"2019","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0600","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1093\/brain\/awp296","article-title":"Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis","volume":"133","author":"Peferoen","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0605","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1073858410381531","article-title":"The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis","volume":"17","author":"Pender","year":"2011","journal-title":"Neuroscientist"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0610","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2017.25","article-title":"Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis","volume":"6","author":"Pender","year":"2017","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0615","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis","volume":"3","author":"Pender","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104497","article-title":"The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment","volume":"70","author":"Pham","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0625","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1352458514530489","article-title":"Responder definition of the multiple sclerosis impact scale physical impact subscale for patients with physical worsening","volume":"20","author":"Phillips","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0630","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1002\/jmv.26188","article-title":"Epstein-Barr virus-immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice","volume":"93","author":"Polepole","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0635","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0640","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.msard.2013.12.004","article-title":"Multiple sclerosis therapy and Epstein-Barr virus antibody titres","volume":"3","author":"Raffel","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0645","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1182\/blood-2007-10-117655","article-title":"LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1","volume":"111","author":"Rastelli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0650","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/jnnp.73.6.701","article-title":"Multiple sclerosis impact scale (MSIS-29): reliability and validity in hospital based samples","volume":"73","author":"Riazi","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0655","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/icb.2016.55","article-title":"Interferon-beta therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis","volume":"94","author":"Rizzo","year":"2016","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105037","article-title":"Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy","volume":"79","author":"R\u00f8d","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0665","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000975","article-title":"Anti-CD20 disrupts meningeal B-cell aggregates in a model of secondary progressive multiple sclerosis","volume":"8","author":"Roodselaar","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0670","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.msard.2019.07.028","article-title":"Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis","volume":"35","author":"Rooney","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0675","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181d865a1","article-title":"Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis","volume":"74","author":"Sargsyan","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0680","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1212\/WNL.58.8.1294","article-title":"Quantitative functional measures in MS: what is a reliable change?","volume":"58","author":"Schwid","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0685","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain","volume":"204","author":"Serafini","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0690","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/jnnp.2011.240432","article-title":"Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis","volume":"82","author":"Simpson","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0695","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/acn3.411","article-title":"Dimethyl fumarate alters B-cell memory and cytokine production in MS patients","volume":"4","author":"Smith","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0700","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0705","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41564-024-01699-6","article-title":"Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease","volume":"9","author":"Soldan","year":"2024","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0710","doi-asserted-by":"crossref","first-page":"18093","DOI":"10.1073\/pnas.0509311102","article-title":"Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells","volume":"102","author":"Souza","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0715","doi-asserted-by":"crossref","first-page":"e0079524","DOI":"10.1128\/mbio.00795-24","article-title":"Targeted eradication of EBV-positive cancer cells by CRISPR\/dCas9-mediated EBV reactivation in combination with ganciclovir","volume":"15","author":"Sugiokto","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0720","doi-asserted-by":"crossref","DOI":"10.1002\/mpr.2030","article-title":"Validity of the five-item mental health inventory for screening current mood and anxiety disorders in the general population","volume":"33","author":"Ten Have","year":"2024","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0725","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0730","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1304281","article-title":"Mimicking the brain: Epstein-Barr virus and foreign agents as drivers of neuroimmune attack in multiple sclerosis","volume":"14","author":"Thomas","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0735","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3032","article-title":"Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis","volume":"9","author":"Thomas","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0740","doi-asserted-by":"crossref","first-page":"12330","DOI":"10.1128\/JVI.01699-12","article-title":"Persistence of Epstein-Barr virus in self-reactive memory B cells","volume":"86","author":"Tracy","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0745","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1352458515588581","article-title":"Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins","volume":"22","author":"van Nierop","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0750","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1037\/0022-006X.51.5.730","article-title":"The structure of psychological distress and well-being in general populations","volume":"51","author":"Veit","year":"1983","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0755","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2567.2007.02690.x","article-title":"Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level","volume":"123","author":"Venken","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0760","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.cell.2023.11.015","article-title":"Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis","volume":"186","author":"Vietzen","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0765","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J. Exp. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2026.579043_bb0770","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jns.2007.01.065","article-title":"The natural history of relapses in multiple sclerosis","volume":"256","author":"Vollmer","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0775","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1212\/WNL.55.2.178","article-title":"Association between clinical disease activity and Epstein-Barr virus reactivation in MS","volume":"55","author":"Wandinger","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0780","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11481-020-09948-1","article-title":"Antibodies from multiple sclerosis brain identified Epstein-Barr virus nuclear antigen 1 & 2 epitopes which are recognized by Oligoclonal bands","volume":"16","author":"Wang","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0785","doi-asserted-by":"crossref","first-page":"eadi0295","DOI":"10.1126\/scitranslmed.adi0295","article-title":"B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans","volume":"16","author":"Wang","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0790","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0795","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2025.12.046","article-title":"EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation","volume":"189","author":"Wang","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0800","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S0140-6736(81)91527-0","article-title":"Multiple sclerosis and Epstein-Barr virus","volume":"2","author":"Warner","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0805","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.nurt.2007.08.002","article-title":"Mechanism of action of glatiramer acetate in treatment of multiple sclerosis","volume":"4","author":"Weber","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0810","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.apmr.2013.07.008","article-title":"Measurement characteristics and clinical utility of the 29-item multiple sclerosis impact scale","volume":"95","author":"Widener","year":"2014","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0815","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1093\/brain\/awp200","article-title":"Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain","volume":"132","author":"Willis","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2026.579043_bb0820","article-title":"Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0825","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0830","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14737175.2016.1181543","article-title":"Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine","volume":"16","author":"Zivadinov","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jneuroim.2026.579043_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104094","article-title":"Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study","volume":"67","author":"Zivadinov","year":"2022","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282600192X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282600192X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:25:44Z","timestamp":1788873944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557282600192X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":167,"alternative-id":["S016557282600192X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579043","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epstein\u2013Barr virus and multiple sclerosis: Mechanisms, therapeutic implications, and emerging interventions","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"579043"}}